Abstract
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
MeSH terms
-
Abdominal Fat / drug effects
-
Abdominal Fat / metabolism
-
Animals
-
Clinical Trials as Topic / methods
-
Growth Hormone-Releasing Hormone / analogs & derivatives*
-
Growth Hormone-Releasing Hormone / pharmacokinetics
-
Growth Hormone-Releasing Hormone / therapeutic use*
-
HIV-Associated Lipodystrophy Syndrome / drug therapy*
-
HIV-Associated Lipodystrophy Syndrome / metabolism
-
Humans
Substances
-
Growth Hormone-Releasing Hormone
-
tesamorelin